AIP and the somatostatin system in pituitary tumours
dc.contributor.author | Ibáñez-Costa, A | en_US |
dc.contributor.author | Korbonits, M | en_US |
dc.date.accessioned | 2018-03-05T10:11:25Z | |
dc.date.available | 2017-08-22 | en_US |
dc.date.issued | 2017-12-01 | en_US |
dc.date.submitted | 2018-03-01T07:49:42.326Z | |
dc.identifier.issn | 0022-0795 | en_US |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/34264 | |
dc.description.abstract | © 2017 Society for Endocrinology Printed in Great Britain. Classic somatostatin analogues aimed at somatostatin receptor type 2, such as octreotide and lanreotide, represent the mainstay of medical treatment for acromegaly. These agents have the potential to decrease hormone secretion and reduce tumour size. Patients with a germline mutation in the aryl hydrocarbon receptor-interacting protein gene, AIP, develop young-onset acromegaly, poorly responsive to pharmacological therapy. In this review, we summarise the most recent studies on AIP-related pituitary adenomas, paying special attention to the causes of somatostatin resistance; the somatostatin receptor profile including type 2, type 5 and truncated variants; the role of G proteins in this pathology; the use of first and second generation somatostatin analogues; and the role of ZAC1, a zinc-finger protein with expression linked to AIP in somatotrophinoma models and acting as a key mediator of octreotide response. | en_US |
dc.description.sponsorship | People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme (FP7/2007–2013) under REA grant agreement n° 608765; Rosetrees Trust (M505) and Medical Research Council (MR/ M018539/1). | en_US |
dc.format.extent | R101 - R116 | en_US |
dc.language | eng | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Journal of Endocrinology | en_US |
dc.title | AIP and the somatostatin system in pituitary tumours | en_US |
dc.type | Article | |
dc.identifier.doi | 10.1530/JOE-17-0254 | en_US |
pubs.issue | 3 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 235 | en_US |
dcterms.dateAccepted | 2017-08-22 | en_US |
Files in this item
This item appears in the following Collection(s)
-
Centre for Endocrinology [552]